Aptalis is a privately held, leading specialty pharmaceutical company providing innovative, effective therapies for unmet medical needs, including cystic fibrosis and gastrointestinal disorders.
All of Aptalis’s activities underscore the Company's single, well-defined mission: to improve the quality of care and health of patients around the world suffering from cystic fibrosis and gastrointestinal disorders by providing effective therapies for patients and their specialized caregivers.
Through internal product development and synergistic acquisitions of products and companies, Aptalis has built a leadership position in the North American gastroenterology market; just under 85 percent of the Company's business is generated from North American sales. Since Aptalis markets its specialized products to a relatively cohesive community of physicians, its sales forces are able to reach this market more easily than pharmaceutical companies with a product portfolio targeting a more diverse range of diseases. Aptalis's products are marketed by its own dedicated and specialized sales forces both in North America and the European Union.
Aptalis and its global operations are working hand-in-hand to become a multinational leader for disorders linked to gastroenterology. Currently, the Company markets more than 40 products and dosage strengths worldwide in the field of gastroenterology, including several that hold a leading market position.
In addition to its marketing activities, Aptalis carries out research and development of products at an advanced stage of development that it acquires or licenses from third parties. By combining its marketing expertise with its research and development experience, Aptalis distinguishes itself from specialty pharmaceutical companies that focus solely on the distribution of products and offers potential licensors the prospect of rapidly expanding the market for their products.
Aptalis’s unique expertise in its field, combined with its excellent industry reputation and international reach, has enabled the Company to maintain its consistent growth trend and attain its strong market position. Aptalis’s solid and stable base business provides a platform for the Company to capitalize on its proven business strategy, in order to continue to achieve significant future growth.
The Company plans to continue to grow its business by:
- increasing market penetration and sales of existing products;
- developing and obtaining marketing approval for new products;
- in-licensing products and acquiring new products or companies;
- development of its research and development portfolio, and expanding geographically.
